

NCCN Malignant Pleural Mesothelioma Guidelines V.1.2012 – Meeting – 06/17/11

Guideline Page and Request	Panel Discussion	References	Vote		
			Yes	No	Abstain
MPM-3 Internal request: Modify the treatment options for operable, clinical stage I to be the same as operable, clinical stage II-III.	The panel consensus was to modify the treatment recommendations for operable, clinical stage I to be the same as operable, clinical stage II-III. This change resulted in the addition of induction chemotherapy with pemetrexed and cisplatin as a primary treatment option, and chemotherapy for unresectable disease after surgical exploration.	<ul style="list-style-type: none"> • Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. <i>J Clin Oncol</i> 2003;21:2636-2644. • Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma. <i>Ann Oncol</i> 2008;19:370-373. • Nowak AK, Byrne MJ, Willianson R, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. <i>Br J Cancer</i> 2002;87:491-496. • Van Haarst JM, Baas J, Manegold CH, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. <i>Br J Cancer</i> 2002; 86:342-345. • Taylor P, Castagneto B, Dark G, et al. Single-agent pemetrexed for chemo-naïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. <i>J Thorac Oncol</i> 2008;3:764-771. • Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. <i>J Clin Oncol.</i> 2009;27:3007-3013. 	29	0	0

NCCN Malignant Pleural Mesothelioma Guidelines V.1.2012 – Meeting – 06/17/11

Guideline Page and Request	Panel Discussion	References	Vote		
			Yes	No	Abstain
MPM-3 Internal request: Modify the adjuvant therapy recommendations after surgical exploration to be the same as those following surgical exploration following induction chemotherapy with pemetrexed and cisplatin.	The panel consensus was to modify the adjuvant treatment recommendations after primary treatment with surgical exploration to be the same as after surgical exploration following induction chemotherapy with pemetrexed and cisplatin. This change resulted in the deletion of adjuvant chemotherapy followed by RT and adjuvant RT followed by chemotherapy after primary treatment with surgical exploration. Chemotherapy is recommended for patients who are unresectable after primary treatment with surgical exploration.	<ul style="list-style-type: none"> • Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. <i>J Clin Oncol</i> 2003;21:2636-2644. • Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma. <i>Ann Oncol</i> 2008;19:370-373. • Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. <i>J Clin Oncol</i> 2006;24:1443-1448. • Nowak AK, Byrne MJ, Willianson R, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. <i>Br J Cancer</i> 2002;87:491-496. • Van Haarst JM, Baas J, Manegold CH, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. <i>Br J Cancer</i> 2002; 86:342-345. • Taylor P, Castagneto B, Dark G, et al. Single-agent pemetrexed for chemo-naïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. <i>J Thorac Oncol</i> 2008;3:764-771. • Muers MF, Stephens RJ, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. <i>Lancet</i> 2008;371:1685-1694. 	29	0	0